Loading the session
Loading the session
Loading instrument
$6.57
−4.92%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:27 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −7.9% (SPY −1.6%). 3 months: −29.3% (SPY −0.4%). 1 year: −25.3% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IMTX, SPY · as of 4 Nov 2026
Closed at $6.91 on 4 Nov 2026: 44.3% below the 52-week high of $12.41 (4 Dec 2025) and 3.9% above the low of $6.65 (16 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
The 4 Nov 2026 close of $6.91 was 15.0% below its 50-day average ($8.13) and 27.6% below its 200-day average ($9.55). It has closed below the 200-day for 85 sessions, since 8 Jul 2026. The 50-day average crossed below the 200-day on 22 Jul 2026, 74 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
3.7M shares were sold short at the 15 Oct 2026 settlement, 2.7% of the 136.7M shares outstanding; covering them would take 3.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
May 24, 2024
+19.14%May 2, 2023
+27.46%July 19, 2022
+17.96%